Therapeutic application of IGF-I in the treatment of neurodegenerative disorders;Emploi therapeutique de l'IGF-I dans le traitement de maladies neurodegeneratives

Medecine/Sciences

Volumn 13, Issue 4, 1997, Pages 557-565

  Doré, Sylvain ^a   Kar, Satyabrata ^a   Quirion, Rémi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROTRANSMITTER; SOMATOMEDIN C;

ADVERSE DRUG REACTION; AMYOTROPHIC LATERAL SCLEROSIS; CELL DIFFERENTIATION; CELL DIVISION; CELL MATURATION; HUMAN; NERVE CELL PLASTICITY; NERVE DEGENERATION; NEUROTRANSMITTER RELEASE; PROTEIN INDUCTION; REVIEW;

EID: 0030900815     PISSN: 07670974     EISSN: None     Source Type: Journal    
DOI: 10.4267/10608/412     Document Type: Review

References (36)

1. de Pablo F, de la Rosa EJ. The developing CNS: a scenario for the action of proinsulin, insulin and insulin-like growth factors. Trends Neurosci 1995; 18: 143-50.
2. Le Roith D, Werner H, Beitner-Johnson D, Roberts CT. Molecular and cellular aspects of the insulin-like growth factor I receptor. Endocrine Rev 1995; 16: 143-63.
3. Joshi R, Jami J. Invalidation chez la souris de gènes susceptibles d'être impliqués dans les diabètes non insulinodépendants. Med Sci 1996; 12: 620-3.
4. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: Biological actions. Endocrine Rev 1995; 16: 3-34.
5. Harel L. Les propriétés multiples des protéines de liaison des IGF (insulin-like growth factors): inhibiteurs et activateurs de croissance. Med Sci 1996; 12: 359-63.
6. Ishii DN, Glazner GW, Pu SF. Role of insulin-like growth factors in peripheral nerve regeneration. Pharmacol Ther 1994; 62: 125-44.
7. Lewis ME, Neff NT, Contreras PC, Stong DB, Oppenheim RW, Grebow PE. Vaught JL. Insulin-like growth factor-I: potential for treatment of motor neuronal disorders. Exp Neurol 1993; 124: 73-88.
8. Henderson C. L'avenir thérapeutique des facteurs neurotrophiques dans les maladies neuro-dégénératives. Med Sci 1995; 11: 1057-9.
9. Nachemson AK, Hansson HA, Lundborg G. Neurotropism in nerve regeneration: an immunohistochemical study. Acta Physiol Scand 1988; 133: 139-48.
10. Doré S, Kar S, Quirion R. Rediscovering an old friend, IGF-I: potential use in the treatment of neurodegenerative diseases. Trends Neurosci 1997 (sous presse).
11. Contreras PC, Steffler C, Yu E, Callison K, Stong D, Vaught JL. Systemic administration of rhIGF-I enhanced regeneration after sciatic nerve crush in mice. J Pharmacol Exp Ther 1995; 274: 1443-9.
12. Hantai D, Akaaboune M, Lagord C, Murawsky M, Houenou LJ, Festoff BW, Vaught JL, Rieger F, Blondet B. Beneficial effects of insulin-like growth factor-I on wobbler mouse motoneuron disease. J Neuron Sci 1995; 129: 122-6.
13. Murphy MF, Felice K, Gawel M, Gelinas D, Kratz R, Lai F, Lango D, Natter H, Rudnicki S, ALS/North American Myotrophin group. A double-blind, placebo-controlled study of myotrophin (CEP-151) in the treatment of amyotrophic lateral sclerosis. Am Neurol ASS Abstr 1995; 38: 335.
14. Yuen EC, Mobley WC. Therapeutic potential of neurotrophic factors for neurological disorders. Ann Neurol 1996; 40: 346-54.
15. Vlachopapadopoulou E, Zachwieja JJ, Gertner JM, Manzione D, Bier DM, Matthews DE, Slonim AE. Metabolic and clinical response to recombinant human insulin-like growth factor I in myotonic dystrophy - a clinical research center study. J Clin Endocrinol Metab 1995; 80: 3715-23.
16. Doré S, Krieger C, Kar S, Quirion R. Distribution and levels of insulin-like growth factor (IGF-I and IGF-II) and insulin receptor binding sites in the spinal cords of amyotrophic lateral sclerosis (ALS) patients. Mol Brain Res 1996; 41: 128-33.
17. McMorris FA, McKinnon RD. Regulation of oligodendrocyte development and CNS myelination by growth factors - prospects for therapy of demyelinating disease. Brain Pathol 1996; 6: 313-29.
18. Liu X, Yao DL, Bondy CA, Brenner M, Hudson LD, Zhou J, Webster HD. Astrocytes express insulin-like growth factor-I (IGF-I) and its binding protein, IGFBP-2, during demyelination induced by experimental autoimmune encephalomyelitis. Mol Cell Neurosci 1994; 5: 418-30.
19. Gluckman PD, Guan J, Beilharz EJ, Klempt ND, Klempt M, Miller O, Sirimanne E, Dragunow M, Williams CE. The role of the insulin-like growth factor system in neuronal rescue. Ann NY Acad Sci 1993; 692: 138-48.
20. Young D, Dragunow M. Neuronal injury following electrically induced status epilepticus with and without adenosine receptor antagonism. Exp Neurol 1995; 133: 125-37.
21. Beilharz EJ, Bassett NS, Sirimanne ES, Williams CE, Gluckman PD. Insulin-like growth factor II is induced during wound repair following hypoxic-ischemic injury in the developing rat brain. Mol Brain Res 1995 ; 29: 81-91.
22. Zhu CZ, Auer RN. Intraventricular administration of insulin and IGF-I in transient forebrain ischemia. J Cereb Blood Flow Metab 1994; 14: 237-42.
23. 125I-insulin receptor binding sites in the hippocampus of aged memory-impaired and memory-unimpaired rats. Soc Neurosci 1996; 22: 551.
24. Crews FT, McElhaney R, Freund G, Ballinger WE Jr, Raizada MK. Insulin-like growth factor I receptor binding in brains of Alzheimer's and alcoholic patients. J Neurochem 1992; 58: 1205-10.
25. Heyd D, Aebischer P. Les facteurs neurotrophiques et leurs applications thérapeutiques potentielles. Med Sci 1996; 12: 299-302.
26. Konishi Y, Takahashi K, Chui DH, Rosenfeld RG, Himeno M, Tabira T. Insulin-like growth factor II promotes in vitro cholinergic development of mouse septal neurones : comparison with the effects of insulin-like growth factor I. Brain Res 1994 ; 649: 53-61.
27. Kar S, Seto D, Hanisch UK, Quirion R. Insulin-like growth factors I and II (IGF-I and IGF-II): receptor localization and effects on acetylcholine release in the rat hippocampus. Soc Neurosci Abstr 1994; 20: 81.
28. Gage SL, Keim SR, Low WC. Effects of insulin-like growth factor II (IGF-II) on transplanted cholinergic neurones from the fetal septal nucleus. Prog Brain Res 1990; 82: 73-80.
29. Glick RP, Unterman TG, Van-der-Woude M, Blaydes LZ. Insulin and insulin-like growth factors in central nervous system tumors. Part V: production of insulin-like growth factors I and II in vitro. J Neurosurg 1992; 77: 445-50.
30. Nilsen FG, Gammeltoft S. Insulin-like growth factors are mitogens for rat pheochromocytoma PG 12 cells. Biochem Biophys Res Commun 1988; 154: 1018-23.
31. Kato J, Wanebo H, Calabresi P, Clark JW. Basic fibroblast growth factor production and growth factor receptors as potential targets for melanoma therapy. Melanoma Res 1992; 2: 13-23.
32. Laventus E, Parrow V, Nanberg E, Pahlman S. Basic FGF and IGF-I promote differentiation of human SH-SY5Y neuroblastoma cells in culture. Growth Factors 1994 ; 10: 29-39.
33. Iglesias T, Llanos S, Lopez-Barahona M, Seliger B, Rodriguez-Pena A, Bernai J, Munoz A. Induction of platelet-derived growth factor B/c-sis by the v-erbA oncoeene in glial cells. Oncogene 1995; 10: 1103-10.
34. Resnicoff M, Sell C, Rubini M, Coppola D, Ambrose D, Baserga R, Rubin R. Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res 1994; 54: 2218-22.
35. Trojan J, Johnson TR, Rudin SD, Ilan J, Tykocinski ML, Ilan J. Treatment and prevention of rat glioblastoma by immunogenic C6 cells expressing antisense insulin-like growth factor I RNA. Science 1993; 259: 94-7.
36. Long L, Rubin R, Baserga R, Brodt P. Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995; 55: 1006-9.